The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type

Folia Histochemica et Cytobiologica

Volumn 48, Issue 1, 2010, Pages 26-29

  Agrawal, A K ^a   Jelen, M ^a   Rudnicki, J ^a   Grzebieniak, Z ^a   Zysko D ^a   Kielan, W ^a   Slonina J ^a   Marek, G ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Breast cancer; CA 15 3; CEA; Histological type; Serum tumour marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POLAND; PREDICTION; PREOPERATIVE EVALUATION; STEP WISE MULTIPLE REGRESSION; SURGICAL WARD; UNIVERSITY HOSPITAL;

EID: 77954373365     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0030-2     Document Type: Article

References (14)

1. Lindblom A, Liljegren A. Tumour markers in malignancies. Clin Rev. 2000;320:424-427.
2. Molina R, Barak V, van Dalen A. et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-93.
3. Seker D, Kaya O, Adabag A et al. Role of preoperative plasma Ca 15.3 and carcinoembryonic antygen levels in determining histopathologic conventional prognostic factors for breast cancer. World J Surg. 2003;27:519-521.
4. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52:345-51.
5. Al-azawi D, Kelly G, Myers E. et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer. 2006;6:220.
6. Dnistrian AM, Schwartz MK, Greenberg EJ et al. Ca 15.3 and carcinoembryonic antigenin the clinical evaluation of breast cancer. Clin Chim Acta. 1991;200:81-93.
7. World Health Organisation. International Classification of Diseases. 10th Ed. Geneva; 1998.
8. Kermani IA. Variation of tumor markers in 277 breast cancer cases. Asian Pac J Cancer Prev. 2004;5(3):291-3.
9. Stratil P, Rejthar A, Lang BA et al. Occurrence of carcinoembryonic antigen in tumor tissue and serum of breast cancer patients. Neoplasma. 1988;35:69-76.
10. Böcker W, Schweikhart G, Pollow K et al. Immunohistochemical demonstration of carcinoembryonic antigen (CEA) in 120 mammary carcinomas and its correlation with tumor type, grading, staging plasma-CEA, and biochemical receptor status. Pathol Res Pract. 1985;180:490-7.
11. Park BW, Oh JW, Kim JH et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675-81.
12. Harris L, Frische H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol. 2007;25:5287-5312.
13. Ebeling FG, Stieber P, Untch M et al. Serum CEA and Ca 15.3 as prognostic factors in primary breast cancer. Brit J Cancer. 2002;86:1217-1222.
14. Guadagni F, Ferroni P, Carlini S et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7:2357-62.